XML 52 R36.htm IDEA: XBRL DOCUMENT v3.22.1
COMMERCIALIZATION AGREEMENTS (Details) - USD ($)
1 Months Ended 12 Months Ended
May 13, 2021
Mar. 29, 2021
Mar. 16, 2020
Sep. 30, 2020
Mar. 31, 2020
Jul. 23, 2018
Oct. 19, 2017
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Jun. 30, 2021
Oct. 31, 2015
Nov. 30, 2009
Promissory note                 $ 4,086,000        
Payment for promissory note               $ 4,086,000 215,000        
Brazil [Member]                          
Percentage Of Adult Gaucher Patients Treated With alfataliglicerase               25.00%          
Pfizer [Member]                          
Collaborative Arrangement Profit Share Percentage                         40.00%
Debt Instrument, Face Amount                       $ 4,300,000  
Promissory note       $ 4,300,000                  
Payment on notes payable       $ 430,000                  
Payment for promissory note   $ 4,000,000.0                      
Chiesi US Agreement and Chiesi Ex US Agreement [Member]                          
Non-refundable Payment Receivable             $ 25,000,000.0 $ 50,000,000.0          
Agreement Amendment Payment Receivable               10,000,000.0     $ 10,000,000.0    
Payments in consideration for development services performed               45,000,000.0          
Payments in connection with performance of additional studies               33,600,000          
Recognized revenues related to non-refundable payment               600,000 3,500,000 $ 4,500,000      
Future milestone payment                 $ 10,000,000.0 $ 10,000,000.0      
Chiesi US Agreement [Member]                          
Non-refundable Payment Receivable           $ 25,000,000.0 25,000,000.0            
Additional Amounts Payable To Cover Development Costs           20,000,000.0              
Maximum Entitlement Of Development Costs To Cover Per Year           7,500,000              
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones           $ 760,000,000.0   $ 735,000,000.0          
Chiesi US Agreement [Member] | Maximum                          
Payment On Net Sales Percentage           40.00%   40.00%          
Chiesi US Agreement [Member] | Minimum                          
Payment On Net Sales Percentage           15.00%   15.00%          
Chiesi Ex US Agreement [Member]                          
Non-refundable Payment Receivable             25,000,000.0            
Additional Amounts Payable To Cover Development Costs             25,000,000.0            
Maximum Entitlement Of Development Costs To Cover Per Year             10,000,000.0            
Agreement Amendment Payment Receivable $ 10,000,000.0                        
Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones $ 25,000,000.0                        
Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones             $ 320,000,000.0            
Chiesi Ex US Agreement [Member] | Maximum                          
Payment On Net Sales Percentage             35.00% 35.00%          
Chiesi Ex US Agreement [Member] | Minimum                          
Payment On Net Sales Percentage             15.00% 15.00%          
Kirin Holdings Company, Limited [Member]                          
Recognized revenues related to non-refundable payment         $ 1,000,000.0                
Non-Refundable Future Service Payment     $ 1,000,000.0